Stem cells for drug screening.

Abstract

Current drug screening methods are insufficiently predictive of clinical toxicity and efficacy. Recent advances in stem cell technology have the potential to improve drug screening. For tests of cardiotoxicity and efficacy of cardioactive drugs, cardiomyocytes derived from human embryonic stem cells and/or human induced pluripotent stem cells, collectively termed human pluripotent stem cells (hPSCs), have been utilized as model alternatives to current drug screening platforms. In this review, we report on recent advances in the differentiation of hPSCs to cardiomyocytes and summarize the evidence for pharmacological responses in hPSC-derived cardiomyocytes.

• Authors: Rebecca R Laposa
• Journal: Journal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 58 Issue 3 Pg. 240-5 (Sep 2011) ISSN: 1533-4023 [Electronic] United States
• PMID: 21499120 (Publication Type: Journal Article)

Chemical References

• Cardiovascular Agents

Topics

• Cardiovascular Agents (pharmacology)
• Drug Evaluation, Preclinical (methods)
• Embryonic Stem Cells (cytology, physiology)
• Humans
• Induced Pluripotent Stem Cells (cytology, physiology)
• Myocytes, Cardiac (cytology, drug effects)